StockData
Cencora, Inc. logo

Cencora, Inc. (COR) KPIs and segments

CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 14/3021% above fair value
$350.56−6.38 (-1.79%)

Close on Nov 17, 2026Market cap $66.90BP/E 26.0Yield 0.63%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Cencora · năm tài chính kết thúc ngày 30 tháng 9

Nhìn nhanh KPI của Cencora: 34 chỉ số vận hành, trong đó có Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services và Other, lấy từ 142 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của Cencora kết thúc ngày 30 tháng 9 — Q4 FY26 = CQ3 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Q2 FY24
Q1 FY24
U.S. Healthcare Solutions($M)
74,86168,76576,21280,26571,34366,81972,55571,67167,19261,29365,184
International Healthcare Solutions($M)
7,6807,5667,6249,4577,2536,6976,9597,3827,0527,1237,070
Alliance Healthcare($M)
6,6016,5166,5316,2305,7725,999
Other Healthcare Solutions($M)
1,0791,0491,0931,023925960
U.S. Healthcare Solutions($M)
9669988311,109834945687697698841698
International Healthcare Solutions($M)
166176142191137155165154179193188
U.S. Healthcare Solutions($M)
2,3772,2521,8842,7581,8111,8811,455
International Healthcare Solutions($M)
8228147891,099736716764
International Healthcare Solutions($M)
-62.3-54.7-36.3-100-59.5-57.7-51.0
U.S. Healthcare Solutions($M)
-147-96.4-66.5-189-110-59.4-41.1
Pharmaceutical Distribution and Services — Revenue ($M)($M)4
74,24271,16466,10872,96971,35267,70163,35169,442
Pharmaceutical Distribution and Services — Segment Operating Income ($M)($M)
691664775607615591726569
Pharmaceutical Distribution and Services — Gross Profit Margin (%)(%)
2.3%2.4%2.7%2.3%2.3%2.3%2.6%2.3%
Pharmaceutical Distribution and Services — Operating Expense Ratio (% of Revenue)(%)
1.4%1.5%1.5%1.4%1.4%1.5%1.5%1.5%
Pharmaceutical Distribution and Services — Operating Margin (%)(%)
0.9%0.9%1.2%0.8%0.9%0.9%1.2%0.8%
Specialty Pharmaceutical and Provider Services — Revenue ($M)($M)4
12,17511,64510,47111,09910,54211,13710,41910,490
Specialty Pharmaceutical and Provider Services — Segment Operating Income ($M)($M)
459468399367334380374283
Specialty Pharmaceutical and Provider Services — Gross Profit Margin (%)(%)
12.6%12.9%12.3%9.2%9.2%8.7%9.0%6.1%
Specialty Pharmaceutical and Provider Services — Operating Expense Ratio (% of Revenue)(%)
8.8%8.9%8.5%5.9%6.1%5.3%5.4%3.4%
Specialty Pharmaceutical and Provider Services — Operating Margin (%)(%)
3.8%4.0%3.8%3.3%3.2%3.4%3.6%2.7%
Other (Revised 3-Segment Structure: European Distribution, Animal Health, Profarma & Consulting) — Revenue ($M)($M)7
2,3022,2532,0562,1292,0922,1081,9562,003
Other (Revised 3-Segment Structure) — Operating Income ($M)($M)
10110991.691.474.487.192.997.3
Other (Revised 3-Segment Structure) — Gross Profit Margin (%)(%)
14.3%14.6%15.2%15.2%14.6%15.0%16.3%15.9%
Other (Revised 3-Segment Structure) — Operating Expense Ratio (% of Revenue)(%)
9.9%9.8%10.7%11.0%11.0%10.8%11.5%11.0%
Other (Revised 3-Segment Structure) — Operating Margin (%)(%)
4.4%4.8%4.5%4.3%3.6%4.1%4.8%4.9%
Intersegment Revenue Eliminations (Revised 3-Segment Structure, $M)($M)
-365-308-280-265-258-281-272-447
Intersegment Operating Income Eliminations (Revised 3-Segment Structure, $M)($M)
-1.90-2.70-2.40-2.200-000
Total Segment Operating Income (Revised 3-Segment Structure, $M)($M)
1,2491,2381,2631,0631,0231,0581,192949
U.S. Healthcare Solutions — Segment Revenue ($M)($M)6
78,29174,86168,76576,21274,24671,34366,81972,55571,67167,19261,29365,184
Disaggregated Revenue: Animal Health (MWI Animal Health, $M)($M)
1,5201,4361,4711,4721,3631,3801,4021,3701,3091,286
U.S. Healthcare Solutions — Segment Cost of Goods Sold (ASU 2023-07, $M)($M)
72,48466,51374,32869,53264,93871,101
U.S. Healthcare Solutions — Segment Gross Profit Margin (%)(%)
3.1%3.2%3.3%2.5%2.5%2.5%2.8%2.0%2.3%2.3%2.7%2.4%
U.S. Healthcare Solutions — Segment Operating Expenses (ASU 2023-07, $M)($M)
1,4101,2541,052978936768
U.S. Healthcare Solutions — Segment Operating Expense Ratio (% of Revenue)(%)
1.9%1.9%1.8%1.4%1.4%1.4%1.4%1.1%1.3%1.3%1.4%1.3%
U.S. Healthcare Solutions — Segment Operating Margin (%)(%)
1.3%1.3%1.5%1.1%1.1%1.2%1.4%1.0%1.0%1.0%1.4%1.1%
International Healthcare Solutions — Segment Revenue ($M)($M)9
7,7987,6817,5667,6247,4207,2536,6976,9597,3827,0527,1237,070
International Healthcare Solutions — Constant Currency Revenue YoY Growth (%)(%)
7.8%6.1%7.2%6.2%5.7%8.8%5.7%8.5%7.9%5.8%9.8%8.7%
International Healthcare Solutions — Constant Currency Revenue ($M)($M)
8,0007,7007,2007,4007,80022,90015,2007,7007,50022,1007,4007,200
International Healthcare Solutions — Segment Cost of Goods Sold (ASU 2023-07, $M)($M)
6,8586,7526,8356,5185,9816,195
International Healthcare Solutions — Segment Gross Profit Margin (%)(%)
10.3%10.7%10.8%10.4%10.0%10.1%10.7%11.0%11.2%11.7%12.0%11.6%
International Healthcare Solutions — Segment Operating Expenses (ASU 2023-07, $M)($M)
656639647598562599
International Healthcare Solutions — Segment Operating Expense Ratio (% of Revenue)(%)
8.3%8.5%8.4%8.5%8.2%8.3%8.4%8.6%9.1%9.1%9.2%8.9%
International Healthcare Solutions — Constant Currency Operating Income YoY Growth (%)(%)
18.9%23.1%12.9%-17.0%-6.0%-16.2%-13.9%3.3%-8.0%0.8%22.1%20.2%
International Healthcare Solutions — Constant Currency Operating Income ($M)($M)
155169175137144510360194155597215194
International Healthcare Solutions — Segment Operating Margin (%)(%)
2.0%2.2%2.3%1.9%1.8%1.9%2.3%2.4%2.1%2.5%2.7%2.7%
Other (FY2026 Segment Structure: MWI Animal Health, Profarma & PharmaLex) — Revenue ($M)($M)8
2,3022,2532,0562,1292,0922,1081,9562,003
Other — Disaggregated Revenue: Other Non-Strategic Businesses (Profarma & PharmaLex, $M)($M)
734620658636593623
Other — Segment Cost of Goods Sold (ASU 2023-07, $M)($M)
1,9251,7441,8051,7921,6381,685
Other — Segment Gross Profit ($M)($M)
329312325315318318
Other — Gross Profit Margin (%)(%)
14.3%14.6%15.2%15.2%14.6%15.0%16.3%15.9%
Other — Segment Operating Expenses (ASU 2023-07, $M)($M)
220220233228226220
Other — Operating Expense Ratio (% of Revenue)(%)
9.9%9.8%10.7%11.0%11.0%10.8%11.5%11.0%
Other — Segment Operating Income ($M)($M)
10110991.691.474.487.192.997.3
Other — Segment Operating Margin (%)(%)
4.4%4.8%4.5%4.3%3.6%4.1%4.8%4.9%
Total Segment Operating Income (Pre-Reconciliation Subtotal, $M)($M)3
1,2491,2381,2631,0631,0231,0581,1929498518781,034886
Intersegment Revenue Eliminations ($M)($M)
-36.8-39.7-30.5-32.7-29.7-40.2-18.8-29.6-3.10-2.10-2-1.20
Consolidated Cost of Goods Sold (ASU 2023-07 Segment Footnote Total, $M)($M)
81,23274,98282,93977,80372,53978,952
Total Segment Operating Expenses (ASU 2023-07 Segment Footnote Total, $M)($M)
2,2852,1111,9311,8021,7231,586
GLP-1 Medications (Diabetes / Weight-Loss) — YoY Revenue Increase ($M)($M)2
2,8002,3001,9001,0008761,4002,2003,2003,1002,1001,3002,100
Manufacturer List Price Reductions — YoY Revenue Headwind ($M)($M)
2,8002,4002,000
Sales to Two Largest Customers (Walgreens & Evernorth) — YoY Revenue Increase ($M, FY2023–FY2025)($M)
6001,4008003,3003,5002,0002,5003,200
Working Capital Efficiency: Days Sales Outstanding (DSO, Days)(ngày)2
272828282828293028
Days Inventory on Hand (DIO, Days)(ngày)
273028272926262827
Days Payable Outstanding (DPO, Days)(ngày)
606559596159606260
Right to Recover Assets (Merchandise Returns Inventory Asset, $M)($M)2
1,2771,5691,5751,6621,6261,4311,3021,1931,1761,1441,1951,243
LIFO Expense / (Credit) Pre-Tax Charge ($M)($M)
-5.60-94.3-210-77.6-57-52.139.5-7.3012.36.80-22.8-48.4
Allowance for Doubtful Accounts / Expected Credit Losses ($M)($M)
1,7351,7111,8351,7961,5931,4381,3271,3081,2711,3311,371
Non-GAAP Adjusted Operating Income ($M)($M)12
1,2491,2381,2631,0631,0231,0581,1929498518781,034886
Non-GAAP Adjusted Gross Profit ($M)($M)
3,5723,5233,3742,9932,9042,8602,9152,5352,4532,3702,5302,389
Non-GAAP Adjusted Operating Expenses ($M)($M)
2,3232,2852,1111,9311,8811,8021,7231,5861,6021,4921,4961,504
Non-GAAP Adjusted Income Before Income Taxes ($M)($M)
1,1231,1021,1319949569891,090917836852968840
Non-GAAP Adjusted Income Tax Expense ($M)($M)
227219214189197205227183169179202176
Non-GAAP Adjusted Net Income Attributable to Cencora, Inc. ($M)($M)
893869928797751781863728662668765661
Non-GAAP Adjusted Diluted Earnings Per Share ($/Share)($)
4.664.484.754.083.8444.423.733.343.343.803.28
Non-GAAP Adjusted Gross Profit Margin (%)(%)
4.0%4.2%4.3%3.5%3.5%3.6%3.9%3.1%3.1%3.2%3.7%3.3%
Non-GAAP Adjusted Operating Expense Ratio (% of Revenue)(%)
2.6%2.7%2.7%2.3%2.3%2.2%2.3%2.0%2.0%2.0%2.2%2.1%
Non-GAAP Adjusted Operating Margin (%)(%)
1.4%1.5%1.6%1.2%1.2%1.3%1.6%1.2%1.1%1.2%1.5%1.2%
Consolidated GAAP Gross Profit Margin (%)(%)
4.1%4.3%4.6%3.6%3.5%3.6%4.1%3.1%3.2%3.3%3.7%3.4%
Consolidated GAAP Operating Expense Ratio (% of Revenue)(%)
3.1%2.9%3.1%2.7%3.5%2.5%2.7%2.3%3.0%2.3%2.9%2.3%
Consolidated GAAP Operating Margin (%)(%)
1.0%1.3%1.5%0.9%0.0%1.1%1.4%0.9%0.2%0.9%0.8%1.1%
Pre-Tax Non-GAAP Adjustment: Acquisition-Related Intangibles Amortization ($M)($M)6
116117116125126125137165166164165166
Pre-Tax Adjustment: Litigation & Opioid-Related Expenses / (Credit), Net ($M)($M)
12.1-88.613.9-86.214.41811.516.865.514.5226-78.9
Accrued Opioid & Litigation Liability — Noncurrent Balance ($M)($M)
3,6703,7743,8573,8693,8814,2854,2854,2974,2974,6984,7204,732
Pre-Tax Adjustment: Acquisition & Divestiture-Related Deal and Integration Expenses ($M)($M)
17711316478.410052.899.438.733.625.822.621.1
Pre-Tax Adjustment: Restructuring & Other Expenses ($M)($M)
65.160.640.914.28941.852.945.881.342.375.634.4
Pre-Tax Adjustment: Gains from Antitrust Litigation Settlements ($M)($M)
-38.4-5.50-16.5-12.2-5.40-9.50-199-22.9-62.3-51.6-8.70-48.2
Pre-Tax Adjustment: Türkiye Highly Inflationary Accounting Impact ($M)($M)
15.415.412.210.913.214.814.57.2010.23.6023.117.2
Non-GAAP Adjusted Free Cash Flow ($M)($M)
2,6662,4231,157-2,4372,878-83.53,024-2,848756763
Consolidated Constant Currency Revenue ($M)($M)1
88,60084,80078,00085,70083,600238,100157,50081,70079,200215,70068,70072,400
Consolidated Constant Currency Adjusted Operating Income ($M)($M)
1,2521,2411,2621,0581,0003,2122,1609618522,8351,100892
U.S. Federal Government Contract Obligations to Cencora / AmerisourceBergen (VA / DoD / HHS, $M)($M)
5432,1412,0901,8112,0991,8811,8071,6471,8361,190757578
Peer Benchmark: McKesson Corporation (MCK) — Consolidated Revenue ($M)($M)2
105,380106,158103,15097,82795,29493,65179,28380,898
McKesson (MCK) — Consolidated Gross Profit ($M)($M)
3,6853,6853,5423,2793,2843,2483,1523,152
McKesson (MCK) — Consolidated GAAP Operating Income ($M)($M)
1,3191,6191,4071,0361,2245781,029642
Peer Benchmark: Cardinal Health, Inc. (CAH) — Consolidated Revenue ($M)($M)2
65,62764,00954,87855,26452,27754,86857,442
Cardinal Health (CAH) — Consolidated Gross Profit ($M)($M)
2,3972,3192,1231,9411,9021,9351,854
Cardinal Health (CAH) — Consolidated GAAP Operating Income/(Loss) ($M)($M)
707668730549568369505
Peer Benchmark: Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M)($M)2
1,4421,3511,4351,4161,3331,2791,2271,146
Consolidated Revenue (GAAP, $M)($M)15
88,35584,75578,35685,93283,72980,66475,45481,48779,05074,24168,41472,253
Cost of Goods Sold (GAAP, $M)($M)
84,75481,14874,76882,86080,77577,75672,39478,92976,55871,83165,87669,784
Gross Profit (GAAP, $M)($M)
3,6013,6073,5883,0722,9542,9073,0602,5582,4922,4112,5382,469
Distribution, Selling & Administrative Expenses (GAAP, $M)($M)
2,1732,1331,9781,7951,7491,6731,6001,4721,4901,3831,3891,399
Total Operating Expenses (GAAP, $M)($M)
2,6942,2852,1111,9311,8811,8021,7231,586
Restructuring & Other Expenses, Net (GAAP Income Statement, $M)($M)
65.160.640.914.28941.852.945.881.342.375.634.4
Litigation & Opioid-Related Expenses / (Credit), Net (GAAP Income Statement, $M)($M)
12.15.5016.512.25.409.5019922.962.351.68.7048.2
Operating Income (GAAP, $M)($M)
9071,1201,14376018.58681,036706127673553823
Income Before Income Taxes (GAAP, $M)($M)
7879962,089709-187896929620125628467783
Income Tax Expense (GAAP, $M)($M)
25822045914314620721112711814145.9180
Net Income Including Noncontrolling Interests (GAAP, $M)($M)
5297771,630566-3336907174947.50488421603
Net Income Attributable to Cencora, Inc. (GAAP, $M)($M)
5197641,641560-3406877184893.40484421602
Diluted Earnings Per Share (GAAP, $/Share)($)
2.713.948.402.873.523.682.502.422.092.98
Basic Earnings Per Share (GAAP, $/Share)($)
2.723.958.442.883.553.702.522.442.113.01
Diluted Weighted-Average Common Shares (Millions)(M)
192194195195195195195200201202
Basic Weighted-Average Common Shares (Millions)(M)
191193195194194194194198199200
Total Assets (GAAP, $M)($M)13
87,10583,80681,65278,36176,59073,95771,19469,05467,10266,77263,86864,690
Cash & Cash Equivalents ($M)($M)
4,8802,8152,1771,7534,3562,2321,9783,2243,1333,3062,0692,872
Accounts Receivable, Net ($M)($M)
26,33425,44824,89325,98025,22524,56223,71524,54623,87224,05222,64321,577
Merchandise Inventories ($M)($M)
21,36421,03020,01024,07920,49320,13818,96620,50818,99918,30217,63118,652
Prepaid Expenses & Other Current Assets ($M)($M)
697636637678539451575516539460512493
Total Current Assets ($M)($M)
58,45255,33553,14154,15252,23948,81446,53549,98747,71847,30744,16144,859
Property & Equipment, Net ($M)($M)
3,0392,8382,8052,4512,5392,4312,3032,1002,1812,0812,0902,117
Other Long-Term Assets ($M)($M)
3,1343,0073,0064,1434,1534,2284,1683,8893,6373,5303,5663,459
Accounts Payable ($M)($M)
58,01154,70051,88256,06454,72051,04450,11149,91150,94249,88346,32147,744
Accrued Expenses & Other Current Liabilities ($M)($M)
3,2603,3493,1962,7262,9832,7172,4482,3852,7592,5262,3722,437
Total Current Liabilities ($M)($M)
62,38159,19756,13259,13257,82153,95853,32854,50954,27752,97449,76250,774
Long-Term Debt ($M)($M)
11,06311,44412,1837,5807,5438,0447,0865,9353,8124,1664,1804,186
Other Long-Term Liabilities ($M)($M)
4,1553,9693,7953,6983,6403,5403,4222,0621,9941,9341,9621,912
Total Stockholders' Equity / (Deficit) ($M)($M)
3,6813,2393,5852,0961,7472,2101,1803627871,0611,2271,061
Operating Cash Flow (GAAP, $M)($M)7
3,1032,6541,339-2,3053,1331093,351-2,7191,0002,478-878885
Capital Expenditures (Additions to Property & Equipment, $M)($M)
39922616611925018312910618211811374.2
Cost of Acquired Companies, Net of Cash Acquired ($M)($M)
-20.9-41.7-4,712-220-91.4-56.5-3,939-9-45.3-22.2-2.300
Net Cash Used in Investing Activities (GAAP, $M)($M)
-386-240-4,875-299-322-235-4,078-343-242-144-167-65.8
Purchases of Common Stock (Cash Flow Statement Outflow, $M)($M)
01,000-0-0-0-05038650555050.8386
Cash Dividends Paid on Common Stock ($M)($M)
116117118127108108111111101103107106
Net Cash Provided by / (Used in) Financing Activities (GAAP, $M)($M)
-601-1,7683,97943.2-684216-4923,209-957-1,145323-552
Net Change in Cash, Cash Equivalents & Restricted Cash ($M)($M)
2,107629428-2,5862,11996.8-1,21697.1-1791,191-751283

18 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Revised 3-Segment Reporting Structure (effective FY2027, restated across FY2025Q1–FY2026Q4 and FY2025–FY2026 in Form 8-K Exhibit 99.1 filed November 4, 2026) disaggregates Cencora into Pharmaceutical Distribution and Services ($284,484.2M revenue and $2,736.4M operating income in FY2026), Specialty Pharmaceutical and Provider Services ($45,356.3M revenue and $1,693.0M operating income in FY2026, encompassing U.S. specialty distribution, OneOncology, Retina Consultants of America, World Courier, and Innomar), and Other ($9,613.2M revenue and $392.9M operating income in FY2026; Intersegment operating income eliminations of -$9.2M).
  • Historical 2-Segment + Other structure (U.S. Healthcare Solutions, International Healthcare Solutions, and Other across 24 quarters FY2021Q1–FY2026Q4 and 6 fiscal years FY2021–FY2026) is enriched with ASC 606 disaggregated revenue (Human Health, Animal Health / MWI, Alliance Healthcare European Distribution, Other International Healthcare Solutions, and Other Non-Strategic Businesses across 28 periods), ASU 2023-07 significant segment expenses (Segment Cost of Goods Sold and Segment Operating Expenses), MD&A Segment Gross Profit, Constant Currency YoY growth rates, and legacy pre-FY2021Q4 segment history.
  • Operational, working capital, and balance-sheet drivers extracted from Form 10-K/10-Q MD&A, Footnotes, and Earnings Releases include GLP-1 medications YoY revenue increases (+$2,800M in Q4 FY2026, +$8,900M in FY2025, +$8,600M in FY2024, +$5,400M in FY2023), manufacturer list price reduction revenue headwinds ($2,000M–$2,800M per quarter in Q2–Q4 FY2026), Working Capital Turnover Days (Days Sales Outstanding 27.1 days, Days Inventory on Hand 26.6 days, Days Payable Outstanding 59.7 days in Q3 FY2026 across 30 periods), Right to Recover customer return assets ($1,276.5M in Q4 FY2026), LIFO inventory reserves ($1,458.9M in FY2025), noncurrent accrued opioid litigation liabilities ($3,670.1M in Q4 FY2026), Walgreens Boots Alliance (26%) & Evernorth (13%) customer concentration, consolidated Brazil VIE (Profarma) balance sheet series, ASC 842 operating lease metrics, and 90 consecutive months of share repurchases (October 2018–June 2026).
  • Only directly reported point figures and cumulative year-to-date period splits (`Q4 = full year − nine months` on ASC 606 disaggregated revenue, ASU 2023-07 segment costs, MD&A segment gross profit, GLP-1 / top-2 customer YoY increases, and GAAP cash flows) are included; no self-computed ratios, margins, or growth rates are added. Consolidated-minus-standalone parent subtraction is not applicable because Cencora, Inc. files consolidated U.S. GAAP financial statements on Form 10-K without standalone parent-company operating revenue.
  • Metrics disclosed only as approximate bounds in recent periods (Total global headcount 'more than 46,000' in FY2024 and 'more than 51,000' in FY2025; Good Neighbor Pharmacy network 'more than 4,800 / nearly 5,000' pharmacies; single-event MSO acquisition provider bounds) are excluded from active series and documented in `excluded`.

Không hiện vì thiếu các kỳ gần đây (5)

  • Global Workforce & Human Capital › Total Employees Worldwide (FY2024–FY2025) — Disclosed only as bounds ('more than 46,000' in FY2024 and 'more than 51,000' in FY2025) in Form 10-K Item 1; Full-Time Employees (47,000 in FY2025) is retained as an exact/approximate series, and FY2019–FY2023 Total Employees is retained as a legacy series
  • Distribution & MSO Network › Good Neighbor Pharmacy / Elevate Provider Network Member Pharmacies — Disclosed only as bounds ('more than 4,800', 'nearly 5,000', or 'thousands of independent community pharmacies') in Form 10-K and ESG reports
  • Management Services Organizations (MSOs) › OneOncology, Retina Consultants of America (RCA) & American Oncology Network (AON) Provider / Clinic Counts — Disclosed as single-event acquisition bounds ('more than 350 oncology providers across 21 states' for AON; 'nearly 300 retinal physicians across 250+ locations' for RCA) in Form 8-K press releases
  • ESG & Operations › Daily Healthcare Products Shipped & Global Operating Locations — Disclosed only as bounds ('more than 6.7 million healthcare products daily', '1,300+ locations', '50+ countries') in Corporate Responsibility Reports
  • ESG & Operations › Occupational Safety Total Recordable Incident Rate (TRIR) & DART — Narrative safety program disclosures in FY2025 Corporate Responsibility Report (GRI 403-9) without a multi-year quantitative rate table

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Cencora

See a number that looks wrong?